Search clinical trials for: Duragesic 25 mcg/h Clinical Procedure 2

Total 85 results

Mylan Pharmaceuticals Inc

Terminated

Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System

Healthy

United States
Alexza Pharmaceuticals, Inc.

Completed

Staccato Fentanyl Single and Multidose PK

Breakthrough Pain

United States
Mylan Pharmaceuticals Inc

Completed

Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System

Healthy

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Fentanyl 25 μg/h Transdermal System

Healthy

Canada
Mylan Pharmaceuticals Inc

Completed

Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System With Askina Derm Overlay

Healthy

United States
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
Medtronic - MITG

Completed

Evaluation of PillCam® Colon 2 Capsule Endoscopy Regimen

Endoscopy | Colonoscopy

United States
GlaxoSmithKline

Withdrawn

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany
AstraZeneca

Completed

A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma (PASSION)

Asthma

Turkey
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
University Hospital Dubrava

Recruiting

Evaluation of Intraoperative Dexmedetomidine Use in Patients Undergoing Surgical Aortic Valve Replacement

Aortic Valve Stenosis | Systemic Inflammatory Response

Croatia
University of Sao Paulo General Hospital

Completed

POST-CABGDM: Empagliflozin in Perioperative CABG (POST-CABGDM)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury | Coronary Artery Bypass Surgery

Brazil
Boehringer Ingelheim

Completed

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

Healthy

Germany
GlaxoSmithKline
Q2 Solutions; York Bioanalytical Solution; BI Medical.Inc; SRL Mediserch.Inc; Parexel...

Completed

A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

Asthma

Japan
GlaxoSmithKline

Completed

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Canada, Germany, Spain, United States, Italy, Netherlands, South Africa, Sweden, France, Mexico, Australia
Alexza Pharmaceuticals, Inc.
Atlanta Center for Medical Research

Completed

Staccato Loxapine Multidose PK

Volunteers on Chronic, Stable Antipsychotic Regimens

United States
New York Institute of Technology
Stony Brook University

Unknown

Vitamin B6, B12, Folic Acid and Exercise in Parkinson's Disease

Parkinson's Disease

United States
Centre Hospitalier Universitaire Dijon

Recruiting

Stroke-induced Myocardial Dysfunction: Role of GDF-15 (SMOG-15) Clinical Work Package (SMOG-15)

Ischemic Stroke

France
University of Mississippi Medical Center
Eli Lilly and Company

Recruiting

Empagliflozin in ESKD - A Feasibility Study

Heart Failure | Kidney Failure, Chronic

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.

Type 2 Diabetes

China
CMP Development, LLC

Completed

Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug)

Drug Drug Interaction

India
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; Far Eastern Memorial Hospital

Unknown

Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Taiwan
University of Virginia
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes (EJB051)

Type2 Diabetes | Insulin Sensitivity

United States
Zydus Therapeutics Inc.

Recruiting

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

Cirrhosis | Hepatic Impairment | Cholestatic Liver Disease

United States
Southeast University, China

Completed

Dexmedetomidine on Microcirculation in Septic Shock

Septic Shock

China
Shahid Beheshti University of Medical Sciences

Recruiting

Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation

Kidney Transplant; Complications

Iran, Islamic Republic of
University Hospital, Basel, Switzerland
Centre Hospitalier Universitaire Vaudois; Luzerner Kantonsspital

Recruiting

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia (EMPOWER)

Liver Failure | Hyponatremia | Kidney Failure | SIADH

Switzerland
University Hospital Inselspital, Berne

Completed

Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass

Dumping Syndrome | Hypoglycemia, Reactive

Switzerland
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Tanta University

Active, not recruiting

Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

Diabetic Neuropathy Peripheral

Egypt
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

Empagliflozin and Hepatic Glucose Metabolism

Hepatic Glucose Metabolism

United States
Christian Schulze
Boehringer Ingelheim; Zentrum für Klinische Studien Jena

Completed

Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)

Acute Decompensated Heart Failure

Germany
The First Affiliated Hospital with Nanjing Medical...
Wu Jieping Medical Foundation

Completed

Study on the Level of Neuromuscular Blockade

Neuromuscular Blockade

China
University Health Network, Toronto

Active, not recruiting

Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis (BIOTAPE)

Axial Spondyloarthritis

Canada
Shaymaa Mohammed El-Awady

Recruiting

Evaluation of the Clinical Outcome of Cyclosporine Short Infusion Versus Continuous Infusion Post Allogenic Stem Cell Transplantation

Allogenic Bone Marrow Transplantation

Egypt
International Bio service

Not yet recruiting

Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers

Healthy Volunteer
Fayoum University
Cairo University

Not yet recruiting

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

SGLT2i Kideny Protection Against Contrast in Diabetic Kidney
Boehringer Ingelheim

Completed

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Diabetes Mellitus, Type 2

Japan
Karolinska Institutet

Terminated

Goal Directed Haemodynamic Treatment for Patients With Proximal Femoral Fracture (GDHT)

Femoral Fracture

Sweden
GlaxoSmithKline

Completed

Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients

Pulmonary Disease, Chronic Obstructive

Germany, Sweden, New Zealand, Russian Federation, United Kingdom
Chungbuk National University Hospital

Active, not recruiting

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy (LUCID)

Diabetes Mellitus, Type 2
Amphastar Pharmaceuticals, Inc.

Completed

Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation

Asthma

United States
Khon Kaen University

Completed

Efficacy Study of "Go On" in Magnetic Resonance Imaging (MRI) Improvement in Osteoarthritis (OA) Knee (GoOn MRI)

Osteoarthritis

Thailand
Jeil Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects

Anti-Ulcer Agents

Korea, Republic of
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Ketones, SGLT2, HFrEF

Heart Failure With Reduced Ejection Fraction | Type2diabetes

United States
Xiayun He, MD

Completed

Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Mackay Memorial Hospital

Unknown

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Type2 Diabetes

Taiwan
Olivia Newton-John Cancer Research Institute
Austin Health; Roche Products Pty Limited; Ballarat Health Services

Active, not recruiting

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (FLUORO)

Follicular Lymphoma

Australia
Chiesi Farmaceutici S.p.A.

Withdrawn

TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD

COPD

Search clinical trials for: Duragesic 25 mcg/h Clinical Procedure 2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations